Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273200 | 0.76 | ADORA3 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL3313454 | 0.74 | MIF (0.53) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL13325708 | 0.74 | NPC1 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL729145 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL84864 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL23132987 | 0.74 | NPSR1 (0.53) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL20019155 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL335455 | 0.74 | PKM (0.51) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL504102 | 0.74 | NPSR1 (0.50) | NPSR1FLT3ADORA3NPC1KDM4E | |
| SCHEMBL19748929 | 0.74 | FLT3 (0.58) | NPSR1FLT3ADORA3NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989167-B | 3,6-dibromo or 3-bromoimidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2023-08-22 | — | — | CN | claimed |
| CN-114989167-A | 3,6-dibromo or 3-bromo imidazo [1,2-a ] pyridine derivative and synthesis method thereof | 江苏师范大学 | 2022-09-02 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20060205797-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006019768-A1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| EP-1231212-A1 | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | NPSR1 907/4885FLT3 582/4885ADORA3 1907/4885 |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | NPSR1 517/4885FLT3 4212/4885ADORA3 395/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | NPSR1 517/4885FLT3 4212/4885ADORA3 395/4885 |
| US-20060205797-A1 | Compounds for the treatment of inflammatory disorders | TNF, MMP12, MMP8 | NPSR1 660/4885FLT3 1924/4885ADORA3 3783/4885 |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | CHRNA7, CHRNA5, CHRNA10 | NPSR1 113/4885FLT3 2096/4885ADORA3 20/4885 |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | NPSR1 116/4885FLT3 2043/4885ADORA3 34/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | NPSR1 4063/4885FLT3 1669/4885ADORA3 2943/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | NPSR1 187/4885FLT3 7/4885ADORA3 1748/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | NPSR1 4146/4885FLT3 3874/4885ADORA3 4507/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | NPSR1 3543/4885FLT3 148/4885ADORA3 1376/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | NPSR1 2913/4885FLT3 2057/4885ADORA3 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.